Former Chief Financial Officer · CRISPR Therapeutics AG (CRSP)

Michael Tomsicek

A named executive officer of CRISPR Therapeutics in every fiscal year CompBrief holds from FY2017 to FY2021. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2021

$3,760,766

Salary $435,483Stock awards $1,204,920

FY2020: $2,621,386

6th of 6 named executive officers at Crispr Therapeutics by FY2021 total.

6 named officers on file for CRISPR Therapeutics, FY2021

Michael Tomsicek’s pay file — $29

  • 5 fiscal years of pay, line by line
  • 7 equity grants, each cited to its filing
  • CRSP’s disclosed peer group of 19 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how CRISPR Therapeutics’s whole pay program stands against its peers

  • CRISPR Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on CRSP→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 25, 2022 (DEF 14A).

Free

Get Michael Tomsicek’s full pay file as a PDF — free

More than this page: up to 10 years of Michael’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Michael Tomsicek compensation by year

CRISPR Therapeutics Summary Compensation Table · all 5 fiscal years held
In US dollars, as CRISPR Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2017FY2018FY2019FY2020FY2021
Salary$51,885$380,000$394,250$422,000$435,483
Bonus$50,000$0$0$0$0
Stock awards$0$0$1,462,600$379,695$1,204,920
Option awards$2,035,542$1,653,972$1,948,673$1,563,531$2,108,763
Non-equity incentive$23,987$209,760$228,665$244,760$0
Pension and deferred compensation$0$0$0$0$0
All other$0$9,625$9,800$11,400$11,600
Total$2,161,414$2,253,357$4,043,988$2,621,386$3,760,766

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: CRISPR Therapeutics AG DEF 14A filed April 25, 2022, accession 0000950170-22-006098, and prior-year filings. Open the filing on EDGAR.

How this page was built: the CRISPR Therapeutics AG filed document, accession 0000950170-22-006098. Every figure is read from that document and cited to the page and table it appears in. Filed April 25, 2022.

$2.2M
$2.3M
$4.0M
$2.6M
$3.8M
FY17
FY18
FY19
FY20
FY21
SalaryBonusNon-equity incentiveStock awardsOption awardsAll other

CRISPR Therapeutics’s named executive officers, FY2021

as the company reported each
Named executive officerRoleFY2021 total
Samarth KulkarniChief Executive Officer$17,037,015
Brendan SmithFormer Chief Financial Officer$7,345,040
Tony HoFormer EVP, Research and Development$6,523,643
Lawrence KleinFormer Chief Operating Officer$5,960,500
James KasingerGeneral Counsel$4,642,761
Michael Tomsicek · this pageFormer Chief Financial Officer$3,760,766

The full CRISPR Therapeutics compensation record

free company brief

This page is one person within CRISPR Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are CRISPR Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Michael Tomsicek's compensation dossier · One-time report. No refunds.